SUBSEQUENT EVENTS (Details) (Subsequent Event [Member], USD $) In Millions, unless otherwise specified	Apr. 29, 2013	Apr. 30, 2013 Cash Paid [Member] Hemerus Medical, LLC [Member]	Apr. 30, 2013 Paid Early [Member] Hemerus Medical, LLC [Member]	Apr. 30, 2013 FDA Approval of SOLX [Member] Hemerus Medical, LLC [Member]	Apr. 30, 2013 Future Sales of SOLX [Member] Hemerus Medical, LLC [Member]
Subsequent Event [Line Items]
Term of the Network Plan	3 years
Estimated Restructuring Expense in Next Fiscal Year	$ 23.0
Estimated Restructuring Expense After One Year	8.0
Estimated Non-Cash Cost, Accelerated Depreciation and Asset Write-Downs	5.0
Estimated Capital Expenditures in Next Fiscal Year	36.0
Estiamted Cash Costs to be Incurred in Next Fiscal Year	29.0
Purchase price		23.0	1.0
Contingent consideration, maximum				$ 3.0	$ 14.0